Document is current
Any future updates will be listed below
-
Authors
Delahoussaye, Abagail M.
Abi Jaoude, Joseph
Green, Morgan
Fujimoto, Tara N.
Molkentine, Jessica
Garcia Garcia, Carolina J.
Gay, Jason P.
Feng, Ningping
Marszalek, Joseph
Fowlkes, Natalie
Taniguchi, Cullen M.
-
Funding
Funding for this research was provided by:
NIH NCI (P30CA016672, P30CA016672, P30CA016672, P30CA016672, P30CA016672)
MD Anderson Cancer Support Grant (CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672)
National Institutes of Health (F31DK121384, CA016672)
Cancer Prevention and Research Institute of Texas (RR140012)
V Foundation (V2015-22)
Reaumond Family Foundation
Childress Family Foundation
Mark Foundation
McNair Foundation
- License Information
-
More Information
Article History
Received: 26 August 2021
Accepted: 27 January 2022
First Online: 16 February 2022
Declarations
:
: The University of Texas MD Anderson Cancer Center Institutional Review Board approved all protocols in this study. All mouse work was approved and done in accordance with the Institutional Animal Care and Use Committee of The University of Texas MD Anderson Cancer Center under protocol IACUC #00001252-RN02. The studies were carried out in compliance with ARRIVE guidelines.
: Not applicable.
: Dr. CMT is on the medical advisory board of Accuray and is a paid consultant for Xerient Pharma and Phebra Pty, Ltd. All other authors report no competing interests.
